Significant Agreements - Novartis Option and License Agreement & Stock Purchase Agreement (Details) $ in Thousands			3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 03, 2024 USD ($)	Dec. 28, 2023 USD ($) shares	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue			$ 24,629	$ 4,614	$ 73,723	$ 159,947
Novartis Pharma, AG | 2023 Novartis Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of collaboration programs | Program							2
Shares of common stock | shares		2,145,002
Aggregate purchase price		$ 20,000
Amount of premium		$ 700
Novartis Pharma, AG | Option and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue			$ 15,000
Upfront payment	$ 15,000
Novartis Pharma, AG | Development, regulatory and commercialization milestone | Option and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate maximum milestone payments to be received from collaborative partner	130,000
Novartis Pharma, AG | Sales milestone | Option and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate maximum milestone payments to be received from collaborative partner	$ 175,000